Original InvestigationCarbamylated Low-Density Lipoproteins Induce a Prothrombotic State Via LOX-1: Impact on Arterial Thrombus Formation In Vivo
Under an Elsevier user license
open archive
Key Words
aggregation
arterial thrombosis
chronic kidney disease
platelets
vascular smooth muscle cells
Abbreviations and Acronyms
AoSMC
aortic smooth muscle cell
CKD
chronic kidney disease
cLDL
carbamylated low-density lipoprotein
HAEC
human aortic endothelial cell
LDL
low-density lipoprotein
LOX-1
lectin-like oxidized LDL receptor 1
MAP kinase
mitogen-activated protein kinase
NFκB
nuclear factor kappa B
nLDL
native low-density lipoprotein
PAI-1
plasminogen activator inhibitor type 1
TF
tissue factor
Cited by (0)
The study was supported by grants from the Swiss National Science Foundation and the Swiss Heart Foundation.
Dr. Beer has received grant support and compensation as advisor, speaker, and CME from Bayer, Boehringer-Ingelheim, Sanofi, Pfizer, and Bristol-Myers Squibb. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Drs. Holy and Akhmedov contributed equally to this work.
© 2016 by the American College of Cardiology Foundation. Published by Elsevier.